Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial

By |2024-02-14T13:55:09-05:00February 14th, 2024|

A total of 186 eligible patients were enrolled with 144 evaluable for safety and 124 evaluable for response. The average number of days from biopsy to initiation of the MTB‑recommended combination therapy was 38 days. Patient benefit was exhibited in 65% of all subjects, 67% of neuroblastoma subjects, 73% of CNS tumor subjects, and 60% [...]

Maintenance DFMO Increases Survival in High Risk Neuroblastoma

By |2023-12-06T03:24:53-05:00December 6th, 2023|

High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent relapse following completion of standard therapy (Stratum 1) or after salvage therapy [...]

A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma

By |2023-08-23T16:40:46-04:00May 29th, 2023|

Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A, Dykema K, Hanna G, Ferguson W, Saulnier Sholler GL. A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and [...]

Development of Clinical-Grade Antibodies against Tumor-Specific Mutations to Target Neuroblastoma

By |2023-08-23T16:31:53-04:00October 12th, 2022|

Stephanie C. Pero, Abhinav B. Nagulapally, Linda Mei, Fan Zhang,*, Giselle S. Sholler, David N. Krag, Girja S. Shukla, Development of Clinical-Grade Antibodies against Tumor-Specific Mutations to Target Neuroblastoma, Annals of Clinical & Laboratory Science, vol. 52, no. 3, 2022

A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma

By |2023-08-23T16:28:15-04:00June 18th, 2022|

Giselle Saulnier Sholler, Dan G. Duda, Genevieve Bergendahl, David Ebb, Matija Snuderl, Theodore W. Laetsch, Jennifer Michlitsch, Derek Hanson, Michael S. Isakoff, Kevin Bielamowicz, Jacqueline M. Kraveka, William Ferguson, Peter Carmeliet, Andy De Deene, Lore Gijsen, Rakesh K. Jain, A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma Clin Cancer Research, [...]

A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma

By |2023-08-23T16:26:44-04:00February 6th, 2022|

Jacqueline M. Kraveka,  Elizabeth C. Lewis, Genevieve Bergendahl, William Ferguson, Javier Oesterheld, Elizabeth Kim, Abhinav B. Nagulapally, Karl J. Dykema, Valerie I. Brown, William D. Roberts, Deanna Mitchell,on E Dslin, Derek Hanson, Michael S. Isakoff, Randal K. Wada, Virginia L. Harrod, Jawhar Rawwas, Gina Hanna, William P. D. Hendricks, Sara A. Byron, Matija Snuderl, Jonathan [...]

Identification of Let-7 miRNA Activity as a Prognostic Biomarker of SHH Medulloblastoma

By |2023-08-24T09:21:24-04:00December 28th, 2021|

Maximillian S Westphal 1, Eunjee Lee 1 2, Eric E Schadt 1 2, Giselle S Sholler 3 4, Jun Zhu, Identification of Let-7 miRNA Activity as a Prognostic Biomarker of SHH Medulloblastoma,  Cancers (Basel). 2021 Dec 28;14(1):139.  doi: 10.3390/cancers14010139.

Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion

By |2023-08-23T16:45:28-04:00October 5th, 2021|

 Sara A. Byron*, William P. D. Hendricks*, Abhinav B. Nagulapally*,  Jacqueline M. Kraveka, William S. Ferguson, Valerie I. Brown, Don E. Eslin, Deanna Mitchell, Albert Cornelius, William Roberts, Michael S. Isakoff, Javier E. Oesterheld, Randal K. Wada, Jawhar Rawwas, Kathleen Neville, Peter E. Zage.  Virginia L. Harrod, Genevieve Bergendahl, Elizabeth VanSickle, Karl Dykema, Jeffrey Bond, [...]

The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma

By |2023-08-24T09:23:14-04:00July 24th, 2020|

Tyler Maser, Joseph Zagorski, Shannon Kelly, Anna Ostrander, Austin Goodyke, Abhinav Nagulapally, Jeffrey Bond, Yeonhee Park, Giselle Saulnier Sholler, The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma, Cancer Medicine, July 2020, DOI: 10.1002/(ISSN)2045-7634

Multiple antibodies targeting tumor-specific mutations redirect immune cells to inhibit tumor growth and increase survival in experimental animal models

By |2023-08-24T10:13:33-04:00July 22nd, 2020|

Shukla, G.S., S.C. Pero, Y. Sun, L. Mei, F. Zhang, G. Sholler, and D.N. Krag, Multiple antibodies targeting tumor-specific mutations redirect immune cells to inhibit tumor growth and increase survival in experimental animal models. Clin Transl Oncol, 2020 Jul;22(7):1094-1104

Go to Top